The Dysmenorrhea Treatment Market reached approximately USD 5.31 billion in 2025 and is projected to reach USD 11.83 billion by 2035, expanding at a CAGR of 8.35% during 2026–2035. Rising diagnosis rates, greater awareness of menstrual health, improved access to treatment, and advances in pharmaceutical therapies are supporting market growth.
Non-steroidal anti-inflammatory drugs remain an important treatment option because of their widespread availability and established use for menstrual pain. NSAIDs accounted for approximately 61.4% of the market in 2025, making them the leading treatment category.
Hormonal therapy is gaining momentum as healthcare providers increasingly use hormonal approaches for pain associated with conditions such as endometriosis. The segment is projected to grow at approximately 10.1% CAGR from 2026 to 2035, making it one of the faster-growing treatment categories.
Improved diagnosis of secondary dysmenorrhea is creating additional opportunities. Secondary dysmenorrhea is associated with underlying conditions, including endometriosis and fibroids, and is expected to grow at approximately 9.8% CAGR during the forecast period.
Digital healthcare is also contributing to market development. Telehealth platforms and cycle-tracking applications can help individuals monitor symptoms and connect with healthcare professionals, potentially encouraging earlier diagnosis and treatment.
The continued development of pain-relief medicines, hormonal therapies, digital health tools, and improved diagnostic pathways is expected to support the expansion of dysmenorrhea treatment services worldwide.
